A compound according to Formula (II), or a pharmaceutical acceptable salt thereof, wherein, R 0 is C 1-6 alkyl; C 1-6 haloalkyl; C 1-6 hydroxyalkyl; halo-substituted C 1-6 hydroxyalkyl ; or phenyl optionally substituted with 1-2 substituents independently represented by R 2 ; or R 0 is selected from the group C 3-7 cycloalkyl, a 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms, and a 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; each of which is optionally substituted with 1-2 substituents represented by R 2a ; Ring B is aryl; 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms; 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; or C 3-7 cycloalkyl; each of which is optionally substituted with 1-2 substituents independently represented by R 2a ; X is -(CR 4 R 5 )- or -C(O)-; L 2 is * 2 -(CR 4 R 5 ) 1-2 -; * 2 -(CR 4 R 5 )-C(O)-; * 2 -(CR 4 R 5 )-C(O)-NR-; * 2 -(CR 4 R 5 ) 2 -O-; * 2 -(CR 4 R 5 ) 2 -NR-; * 2 -(CR 4 R 5 ) 2 -NR-SO 2 -; * 2 -(CR 4 R 5 ) 2 -NR-C(O)-; * 2 -(CR 4 R 5 )-C(O)-NR-(CR 4 R 5 )-; or * 2 -(CR 4 R 5 ) 2 -NR-C(O)-NR-(CR 4 R 5 ) 0-1 ; wherein "* 2 " indicates the point of attachment of L 2 to N; each R 2 is independently halo, hydroxyl, C 1-6 alkyl, halo-substituted C 1-6 alkyl, -C(O)NR 6 R 7 ; -S(O) 2 -NR 4 N 5 ; -C(O)O-(CR 4 CR 5 ) 2-3 NR 4 R 5 ; -N(R)-C(O)O-R; -SO 2 R; - NR 4 R 5 or -(CR 4 R 5 )-C(O)OR; each R 2a is independently halo, hydroxyl, C 1-6 alkyl, or halo-substituted C 1-6 alkyl; each R 3 is independently hydrogen, halo, C 1-6 alkyl, C 2-6 alkenyl or cyclopropyl; and R, R 4 , R 5 , R 6 and R 7 are independently hydrogen or C 1-6 alkyl; alternatively R 6 and R 7 together with N may form a 5-6 membered heterocyclic ring. R 0 is C 1-6 alkyl; C 1-6 haloalkyl; C 1-6 hydroxyalkyl; halo-substituted C 1-6 hydroxyalkyl ; or phenyl optionally substituted with 1-2 substituents independently represented by R 2 ; or R 0 is selected from the group C 3-7 cycloalkyl, a 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms, and a 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; each of which is optionally substituted with 1-2 substituents represented by R 2a ; Ring B is aryl; 5-10 membered heteroaryl comprising 1-3 N, O or S heteroatoms; 4-6 membered heterocycle comprising 1-2 N, O or S heteroatoms; or C 3-7 cycloalkyl; each of which is optionally substituted with 1-2 substituents independently represented by R 2a ; X is -(CR 4 R 5 )- or -C(O)-; L 2 is * 2 -(CR 4 R 5 ) 1-2 -; * 2 -(CR 4 R 5 )-C(O)-; * 2 -(CR 4 R 5 )-C(O)-NR-; * 2 -(CR 4 R 5 ) 2 -O-; * 2 -(CR 4 R 5 ) 2 -NR-; * 2 -(CR 4 R 5 ) 2 -NR-SO 2 -; * 2 -(CR 4 R 5 ) 2 -NR-C(O)-; * 2 -(CR 4 R 5 )-C(O)-NR-(CR 4 R 5 )-; or * 2 -(CR 4 R 5 ) 2 -NR-C(O)-NR-(CR 4 R 5 ) 0-1 ; wherein "* 2 " indicates the point of attachment of L 2 to N; each R 2 is independently halo, hydroxyl, C 1-6 alkyl, halo-substituted C 1-6 alkyl, -C(O)NR 6 R 7 ; -S(O) 2 -NR 4 N 5 ; -C(O)O-(CR 4 CR 5 ) 2-3 NR 4 R 5 ; -N(R)-C(O)O-R; -SO 2 R; - NR 4 R 5 or -(CR 4 R 5 )-C(O)OR; each R 2a is independently halo, hydroxyl, C 1-6 alkyl, or halo-substituted C 1-6 alkyl; each R 3 is independently hydrogen, halo, C 1-6 alkyl, C 2-6 alkenyl or cyclopropyl; and R, R 4 , R 5 , R 6 and R 7 are independently hydrogen or C 1-6 alkyl; alternatively R 6 and R 7 together with N may form a 5-6 membered heterocyclic ring. <EOS>